NO20054951L - Prostaglandinanaloger som EP4-reseptorantagonister - Google Patents

Prostaglandinanaloger som EP4-reseptorantagonister

Info

Publication number: NO20054951L
Authority: NO; Norway
Prior art keywords: receptor antagonists; prostaglandin analogues; prostaglandin; analogues; glaucoma
Prior art date: 2003-03-26

Application number

NO20054951A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054951D0 (no

Inventor

Xavier Billot

John Colucci

Yongxin Han

Marie-Claire Wilson

Robert N Young

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-26

Filing date

2005-10-25

Publication date

2005-12-22

2005-10-25 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

2005-10-25 Publication of NO20054951D0 publication Critical patent/NO20054951D0/no

2005-12-22 Publication of NO20054951L publication Critical patent/NO20054951L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Hydrogenated Pyridines (AREA)

NO20054951A 2003-03-26 2005-10-25 Prostaglandinanaloger som EP4-reseptorantagonister NO20054951L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45770003P	2003-03-26	2003-03-26
PCT/CA2004/000471 WO2004085431A1 (en)	2003-03-26	2004-03-26	Prostaglandin analogs as ep4 receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20054951D0 NO20054951D0 (no)	2005-10-25
NO20054951L true NO20054951L (no)	2005-12-22

Family

ID=33098243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054951A NO20054951L (no)	2003-03-26	2005-10-25	Prostaglandinanaloger som EP4-reseptorantagonister

Country Status (22)

Country	Link
US (4)	US7053085B2 (pt)
EP (1)	EP1613621B1 (pt)
JP (1)	JP4866992B2 (pt)
KR (1)	KR20060002873A (pt)
CN (1)	CN1764659A (pt)
AR (1)	AR040806A1 (pt)
AT (1)	ATE474837T1 (pt)
BR (1)	BRPI0408690A (pt)
CA (1)	CA2519938C (pt)
CL (1)	CL2004000655A1 (pt)
DE (1)	DE602004028229D1 (pt)
EC (1)	ECSP056037A (pt)
ES (1)	ES2347434T3 (pt)
HR (1)	HRP20050845A2 (pt)
IS (1)	IS7999A (pt)
MA (1)	MA27667A1 (pt)
MX (1)	MXPA05010189A (pt)
NO (1)	NO20054951L (pt)
PE (1)	PE20050522A1 (pt)
RU (1)	RU2005132930A (pt)
TW (1)	TW200427670A (pt)
WO (2)	WO2004085431A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7053085B2 (en) *	2003-03-26	2006-05-30	Merck & Co. Inc.	EP4 receptor agonist, compositions and methods thereof
CN1735597A (zh) *	2003-01-10	2006-02-15	霍夫曼-拉罗奇有限公司	作为前列腺素激动剂的2－哌啶酮衍生物
US6977260B2 (en)	2004-01-22	2005-12-20	Allergan, Inc.	Piperidinyl prostaglandin E analogs
US7326716B2 (en)	2003-06-06	2008-02-05	Allergan, Inc.	Treatment of inflammatory bowel disease
CA2528179C (en) *	2003-06-06	2013-10-22	Allergan, Inc.	Piperidinyl prostaglandin e analogs
US7179820B2 (en)	2003-06-06	2007-02-20	Allergan, Inc.	Piperidinyl prostaglandin E analogs
WO2005020917A2 (en)	2003-09-02	2005-03-10	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
CA2537410C (en)	2003-09-04	2009-08-11	Merck & Co., Inc.	Ophthalmic indazole comprising compositions for treating ocular hypertension
CA2537430A1 (en)	2003-09-04	2005-03-24	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
US7427614B2 (en)	2004-07-02	2008-09-23	Allergan, Inc.	Prostaglandin analogs
JP2008507521A (ja) *	2004-07-20	2008-03-13	メルク　エンド　カムパニー　インコーポレーテッド	高眼圧症を治療するための眼科用組成物
CA2585367A1 (en) *	2004-10-26	2006-05-04	Allergan, Inc.	Therapeutic and delivery methods of prostaglandin ep4 agonists
US7994195B2 (en) *	2004-11-04	2011-08-09	Allergan, Inc.	Therapeutic substituted piperidone compounds
US7531533B2 (en)	2005-01-27	2009-05-12	Asahi Kasei Pharma Corporation	6-Membered heterocyclic compound and use thereof
WO2006080323A1 (ja) *	2005-01-27	2006-08-03	Asahi Kasei Pharma Corporation	ヘテロ６員環化合物及びその用途
EP1912977A4 (en) *	2005-08-03	2009-10-21	Merck Frosst Canada Ltd	EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
WO2007014462A1 (en) *	2005-08-03	2007-02-08	Merck Frosst Canada Ltd.	Ep4 receptor agonist, compositions and methods thereof
UY30121A1 (es)	2006-02-03	2007-08-31	Glaxo Group Ltd	Nuevos compuestos
US7498447B2 (en)	2006-05-24	2009-03-03	Allergan, Inc.	Therapeutic compounds
US7550448B2 (en)	2006-05-24	2009-06-23	Allergan, Inc.	Therapeutic compounds
WO2008027341A2 (en) *	2006-08-30	2008-03-06	Merck & Co., Inc.	Topical ophthalmic formulations
WO2008027340A2 (en) *	2006-08-30	2008-03-06	Merck & Co., Inc.	Topical ophthalmic formulations
WO2008070310A2 (en)	2006-10-20	2008-06-12	Children's Medical Center Corporation	Method to enhance tissue regeneration
CN101168514B (zh) *	2006-10-26	2011-12-07	上海药明康德新药开发有限公司	光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法
WO2008071736A1 (en)	2006-12-15	2008-06-19	Glaxo Group Limited	Benzamide derivatives as ep4 receptor agonists
GB2446652A (en) *	2007-02-16	2008-08-20	Inion Ltd	Osteogenic compounds
KR20100016299A (ko)	2007-05-08	2010-02-12	고쿠리츠다이가쿠호진 하마마츠이카다이가쿠	Ｅｐ４ 아고니스트를 함유하여 이루어지는 세포 상해성 ｔ 세포의 활성화제
WO2008149965A1 (ja) *	2007-06-07	2008-12-11	Astellas Pharma Inc.	ピリドン化合物
GB0721611D0 (en)	2007-11-02	2007-12-12	Glaxo Group Ltd	Novel compounds
CN101468985A (zh) *	2007-12-28	2009-07-01	中国人民解放军军事医学科学院毒物药物研究所	5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用
US8633310B2 (en) *	2008-02-19	2014-01-21	Allergan, Inc.	Therapeutic substituted lactams
US7964596B2 (en)	2008-03-07	2011-06-21	Allergan, Inc.	Therapeutic compounds
BR112012008959A2 (pt)	2009-10-14	2019-09-24	Gemmus Pharma Inc	tratamento de terapia de combinação para infecções virais
CA2738045C (en)	2010-05-28	2019-02-19	Simon Fraser University	Conjugate compounds, methods of making same, and uses thereof
EP3884935B1 (en)	2013-08-09	2023-06-14	Ardelyx, Inc.	Compounds and methods for inhibiting phosphate transport
US9650414B1 (en)	2014-05-30	2017-05-16	Simon Fraser University	Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh)	2015-06-12	2020-12-15	西蒙弗雷泽大学	酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
WO2017126635A1 (ja) *	2016-01-22	2017-07-27	武田薬品工業株式会社	複素環化合物およびその用途
ES2929799T3 (es)	2017-12-25	2022-12-01	Asahi Kasei Pharma Corp	Compuestos que contienen resto de 2-oxo-1,3,4-tiadiazinan-3-ilo con actividad agonista del receptor EP4
CN114340631A (zh)	2019-05-21	2022-04-12	阿德利克斯股份有限公司	用于降低患者的血清磷酸盐的组合
CN111269193B (zh) *	2020-04-02	2022-05-24	湖南海利常德农药化工有限公司	一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1524818A (en)	1974-11-29	1978-09-13	Beecham Group Ltd	12-azaprostaglandins
US4177346A (en)	1976-08-06	1979-12-04	Pfizer Inc.	1,5-Disubstituted-2-pyrrolidones
EP0008186A1 (en)	1978-08-08	1980-02-20	Beecham Group Plc	Cyclic diamides, a process for their preparation and their pharmaceutical compositions
FR2534580A1 (fr) *	1982-10-13	1984-04-20	Synthelabo	Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) *	1987-09-18	1999-07-06	R Tech Ueno Ltd	Ocular hypotensive agents
US4960771A (en) *	1988-07-12	1990-10-02	Rajadhyaksha Vithal J	Oxazolidinone penetration enhancing compounds
US5296504A (en) *	1988-09-06	1994-03-22	Kabi Pharmacia	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1348437A3 (en) *	1988-09-06	2003-11-19	Pharmacia Aktiebolag	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) *	1992-09-21	1994-10-04	Allergan, Inc.	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en)	1992-12-04	1999-07-13	The Children's Medical Center Corp.	Glaucoma treatment
US5510383A (en) *	1993-08-03	1996-04-23	Alcon Laboratories, Inc.	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH10265454A (ja)	1997-01-27	1998-10-06	Ono Pharmaceut Co Ltd	３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6043275A (en) *	1998-04-16	2000-03-28	Ono Pharmaceutical Co., Ltd.	3,7-dithiaprostanoic acid derivative
KR20010074981A (ko)	1998-09-14	2001-08-09	우에노 도시오	ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
WO2000021542A1 (en)	1998-10-15	2000-04-20	Merck & Co., Inc.	Methods for stimulating bone formation
AU2183900A (en) *	1998-12-24	2000-07-31	Alcon Laboratories, Inc.	Ep4 receptor agonists for treatment of dry eye
EE200200355A (et)	1999-12-22	2003-10-15	Pfizer Products Inc.	EP4 retseptori selektiivsed agonistid osteoporoosi raviks
CA2402403A1 (en)	2000-03-17	2001-09-27	Alcon, Inc.	6-hydroxy-indazole derivatives for treating glaucoma
EP1186287A1 (en)	2000-03-31	2002-03-13	Toray Industries, Inc.	Hair growth or hair formation controlling agents
WO2002024647A1 (fr)	2000-09-21	2002-03-28	Ono Pharmaceutical Co., Ltd.	Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
CN1476429A (zh)	2000-11-27	2004-02-18	�Ʒ�	治疗骨质疏松的ep4受体选择性激动剂
CA2434495A1 (en)	2001-01-30	2002-08-08	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
WO2002077168A2 (en)	2001-03-22	2002-10-03	Merck & Co., Inc.	Mch1r deficient mice
WO2003047513A2 (en)	2001-12-03	2003-06-12	Merck & Co., Inc.	Method for treating ocular hypertension
AU2002346561B2 (en)	2001-12-03	2006-08-17	Merck & Co., Inc.	EP4 receptor agonist, compositions and methods thereof
AU2003239972B2 (en)	2002-06-14	2008-02-28	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
JP2005538061A (ja)	2002-06-17	2005-12-15	メルク　エンド　カムパニー　インコーポレーテッド	新規ｍａｘｉ−ｋチャネルブロッカー、その使用方法および製造方法
JP2005533055A (ja)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	新規マキシｋチャンネルブロッカー、その使用方法および製造方法
US7053085B2 (en) *	2003-03-26	2006-05-30	Merck & Co. Inc.	EP4 receptor agonist, compositions and methods thereof
CN1735597A (zh) *	2003-01-10	2006-02-15	霍夫曼-拉罗奇有限公司	作为前列腺素激动剂的2－哌啶酮衍生物
US6747037B1 (en) *	2003-06-06	2004-06-08	Allergan, Inc.	Piperidinyl prostaglandin E analogs

2004
- 2004-03-10 US US10/797,257 patent/US7053085B2/en not_active Ceased
- 2004-03-24 PE PE2004000303A patent/PE20050522A1/es not_active Application Discontinuation
- 2004-03-24 AR AR20040100984A patent/AR040806A1/es not_active Application Discontinuation
- 2004-03-25 TW TW093108108A patent/TW200427670A/zh unknown
- 2004-03-26 JP JP2006504090A patent/JP4866992B2/ja not_active Expired - Lifetime
- 2004-03-26 RU RU2005132930/04A patent/RU2005132930A/ru not_active Application Discontinuation
- 2004-03-26 CA CA2519938A patent/CA2519938C/en not_active Expired - Lifetime
- 2004-03-26 DE DE602004028229T patent/DE602004028229D1/de not_active Expired - Lifetime
- 2004-03-26 WO PCT/CA2004/000471 patent/WO2004085431A1/en active Application Filing
- 2004-03-26 CN CNA200480008186XA patent/CN1764659A/zh active Pending
- 2004-03-26 EP EP04723484A patent/EP1613621B1/en not_active Expired - Lifetime
- 2004-03-26 ES ES04723484T patent/ES2347434T3/es not_active Expired - Lifetime
- 2004-03-26 KR KR1020057018107A patent/KR20060002873A/ko not_active Application Discontinuation
- 2004-03-26 BR BRPI0408690-2A patent/BRPI0408690A/pt not_active Application Discontinuation
- 2004-03-26 WO PCT/CA2004/000470 patent/WO2004085430A1/en active Application Filing
- 2004-03-26 AT AT04723484T patent/ATE474837T1/de not_active IP Right Cessation
- 2004-03-26 CL CL200400655A patent/CL2004000655A1/es unknown
- 2004-03-26 MX MXPA05010189A patent/MXPA05010189A/es unknown
2005
- 2005-06-07 US US11/146,992 patent/US7238710B2/en not_active Expired - Lifetime
- 2005-08-25 IS IS7999A patent/IS7999A/is unknown
- 2005-09-14 MA MA28497A patent/MA27667A1/fr unknown
- 2005-09-23 HR HR20050845A patent/HRP20050845A2/xx not_active Application Discontinuation
- 2005-09-23 EC EC2005006037A patent/ECSP056037A/es unknown
- 2005-10-25 NO NO20054951A patent/NO20054951L/no unknown
2007
- 2007-04-26 US US11/796,044 patent/USRE42562E1/en not_active Expired - Lifetime
2011
- 2011-06-03 US US13/152,586 patent/US20110237511A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110237511A1 (en)	2011-09-29
CL2004000655A1 (es)	2005-01-21
US7238710B2 (en)	2007-07-03
US20050227969A1 (en)	2005-10-13
TW200427670A (en)	2004-12-16
KR20060002873A (ko)	2006-01-09
JP4866992B2 (ja)	2012-02-01
HRP20050845A2 (en)	2006-05-31
CA2519938A1 (en)	2004-10-07
CA2519938C (en)	2010-11-30
PE20050522A1 (es)	2005-07-06
RU2005132930A (ru)	2006-02-10
CN1764659A (zh)	2006-04-26
BRPI0408690A (pt)	2006-03-28
EP1613621A1 (en)	2006-01-11
MA27667A1 (fr)	2005-12-01
EP1613621B1 (en)	2010-07-21
MXPA05010189A (es)	2006-02-22
AU2004224261A1 (en)	2004-10-07
ATE474837T1 (de)	2010-08-15
US20040198701A1 (en)	2004-10-07
US7053085B2 (en)	2006-05-30
JP2006520758A (ja)	2006-09-14
AR040806A1 (es)	2005-04-20
ES2347434T3 (es)	2010-10-29
DE602004028229D1 (de)	2010-09-02
WO2004085431A1 (en)	2004-10-07
USRE42562E1 (en)	2011-07-19
WO2004085430A1 (en)	2004-10-07
ECSP056037A (es)	2006-01-27
NO20054951D0 (no)	2005-10-25
IS7999A (is)	2005-08-25

Publication	Publication Date	Title
NO20054951L (no)	2005-12-22	Prostaglandinanaloger som EP4-reseptorantagonister
WO2003047513A3 (en)	2004-07-15	Method for treating ocular hypertension
NO20074390L (no)	2007-10-15	Forsterket bimatoprost oye-opplosning
ATE487514T1 (de)	2010-11-15	1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
WO2004037786A3 (en)	2004-09-30	2-pyrrolidones as ep4 receptor agonists
DE602006017694D1 (de)	2010-12-02	C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
NO20076479L (no)	2008-01-29	Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
NO20060195L (no)	2006-03-13	Kinolylamidderivater som CCR-5-antagonister
NO20076060L (no)	2007-12-28	Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
WO2005002520A3 (en)	2005-03-31	Ophthalmic compositions for treating ocular hypertension
DE602005020655D1 (de)	2010-05-27	Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
WO2007108968A3 (en)	2007-11-29	Ophthalmic compositions for treating ocular hypertension
NO20070336L (no)	2007-02-13	Indolderivater som histamin-reseptorantagonister
MY159463A (en)	2017-01-13	Method and composition for treating ocular hypertension and glaucoma
WO2003047417A3 (en)	2003-11-27	Ep4 receptor agonist, compositions and methods thereof
ATE537170T1 (de)	2011-12-15	Cgrp-rezeptorantagonisten
ATE290910T1 (de)	2005-04-15	Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
NO20061981L (no)	2006-07-03	Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
WO2005115392A3 (en)	2006-02-02	3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
EA200901402A1 (ru)	2010-04-30	Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина
NO20052751L (no)	2005-06-07	Oftalmisk preparat for behandling av okulaer hypertensjon.
WO2005020917A3 (en)	2005-05-19	Ophthalmic compositions for treating ocular hypertension
WO2006062731A8 (en)	2007-05-31	Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
AR060222A1 (es)	2008-06-04	Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma
WO2006044425A3 (en)	2006-06-15	Ophthalmic compositions for treating ocular hypertension